Evidence mapPaperPMID 42411587Full record

Trial reportEuropace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology2026

Early recurrence of atrial tachyarrhythmia after catheter ablation and its associations with clinical outcomes, atrial fibrillation burden, and blanking period duration: a post hoc analysis of the CABANA trial.

Hongyu Liu, Runhui Hu, Wenhui Li, Eva Soler-Espejo, Tommaso Bucci, Yang Liu, Manlin Zhao, Tianshu Gu, Weiguo Fan, Bi Huang and 4 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Hongyu LiuDepartment of Cardiovascular Medicine, The Second Affiliated Hospital, School of Basic Sciences, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, People's Republic of China.ORCID 0000-0003-0383-8725
Runhui HuDepartment of Cardiovascular Medicine, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, People's Republic of China.
Wenhui LiLiverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, William Henry Duncan Building, 6 West Derby Street, Liverpool L7 8TX, UK.ORCID 0009-0003-0772-2575
Eva Soler-EspejoLiverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, William Henry Duncan Building, 6 West Derby Street, Liverpool L7 8TX, UK.ORCID 0000-0003-4925-4864
Tommaso BucciLiverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, William Henry Duncan Building, 6 West Derby Street, Liverpool L7 8TX, UK.ORCID 0000-0003-2895-6234
Yang LiuLiverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, William Henry Duncan Building, 6 West Derby Street, Liverpool L7 8TX, UK.ORCID 0000-0003-4430-3452
Manlin ZhaoLiverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, William Henry Duncan Building, 6 West Derby Street, Liverpool L7 8TX, UK.ORCID 0000-0002-5073-1798
Tianshu GuLiverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, William Henry Duncan Building, 6 West Derby Street, Liverpool L7 8TX, UK.
Weiguo FanDepartment of Cardiovascular Medicine, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, People's Republic of China.
Bi HuangLiverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, William Henry Duncan Building, 6 West Derby Street, Liverpool L7 8TX, UK.ORCID 0000-0002-3294-268X
Dhiraj GuptaLiverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, William Henry Duncan Building, 6 West Derby Street, Liverpool L7 8TX, UK.ORCID 0000-0002-3490-090X
Douglas L PackerDepartment of Cardiology, Intermountain Medical Center, Murray, UT, USA.
Yang ChenLiverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, William Henry Duncan Building, 6 West Derby Street, Liverpool L7 8TX, UK.ORCID 0000-0002-2808-6286
Gregory Y H LipLiverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, William Henry Duncan Building, 6 West Derby Street, Liverpool L7 8TX, UK.ORCID 0000-0002-7566-1626

Funding

Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC)NIH HHS
6 · The paper itself

Abstract

aimsEarly recurrence of atrial tachyarrhythmia (ERAT) after catheter ablation for atrial fibrillation (AF) is common, yet its prognostic significance and implications for the duration of the blanking period remain uncertain. We aimed to evaluate the association between ERAT and post-ablation clinical outcomes, late arrhythmia recurrence, and AF burden, and to explore the optimal duration of the blanking period. METHODS AND

resultsThis post hoc analysis included 811 patients from the CABANA trial who underwent catheter ablation and had trial-specific electrocardiographic monitoring data available. ERAT was defined as any episode of AF, atrial flutter, or atrial tachycardia lasting >30 s within the 90-day blanking period. The primary outcome was a composite of all-cause mortality, disabling stroke, serious bleeding, or cardiac arrest. Secondary outcomes included cardiovascular hospitalization and late atrial tachyarrhythmia recurrence. During a median 4 years (IQR 2.5-5.2) follow-up, ERAT occurred in 567 patients (69.9%). Patients with ERAT had higher risks of cardiovascular hospitalization [adjusted hazard ratio (aHR) 1.35, 95% confidence interval (CI) 1.07-1.71] and of the composite outcome of all-cause mortality or cardiovascular hospitalization (aHR 1.33, 95% CI 1.07-1.66), but no increased risk of the primary composite outcome. ERAT was independently associated with late atrial tachyarrhythmia recurrence (aHR 1.35, 95% CI 1.07-1.71). Prognostic relevance varied by timing, with the strongest association observed for ERAT occurring between 60 and 90 days after ablation (aHR 1.80, 95% CI 1.16-2.79). Receiver operating characteristic analysis identified 58 days as the optimal threshold for predicting late arrhythmia recurrence (AUC 0.727).

conclusionERAT was associated with higher risks of cardiovascular hospitalization and late atrial tachyarrhythmia recurrence in a time-dependent manner, supporting a shorter blanking period to better identify patients at risk of adverse rhythm outcomes.

Indexed as

Atrial FibrillationCatheter AblationAgedElectrocardiographyFemaleHospitalizationHumansMaleMiddle AgedRecurrenceRisk FactorsTime FactorsTreatment OutcomeAtrial fibrillationBlanking periodCABANA trialCatheter ablationEarly recurrence of atrial tachyarrhythmia

Identifiers

PMID42411587
PMCPMC13385998

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.